Endothelin and endothelin receptor antagonists in systemic rheumatic disease

Arthritis and Rheumatism

Volumn 48, Issue 5, 2003, Pages 1190-1199

  Mayes, Maureen D ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b MSB 5270   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; SITAXSENTAN;

ACUTE HEPATITIS; ANEMIA; AORTA ARCH SYNDROME; BUERGER DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DYSPNEA; HEADACHE; HUMAN; LUNG FIBROSIS; NOSE CONGESTION; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC DISEASE; SCLERODERMA; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TERATOGENESIS;

ANTIHYPERTENSIVE AGENTS; CONNECTIVE TISSUE DISEASES; CONTROLLED CLINICAL TRIALS; CREST SYNDROME; ENDOTHELINS; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 0037653357     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10895     Document Type: Review

References (108)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
2. Masaki T. The discovery of endothelins. Cardiovasc Res 1998;39: 530-3.
3. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989;86:2863-7.
4. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
5. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
6. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Colch) 1993;84:485-500.
7. Ortega Mateo A, de Artiñano AA. Highlights on endothelins: a review. Pharmacol Res 1997;36:339-51.
8. Teder P, Noble PW. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2000;23:7-10.
9. Michael JRq, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med 1996;154:555-81.
10. McKay KO, Armour CL, Black JL. Endothelin-3 increases transmission in the rabbit pulmonary parasympathetic nervous system. J Cardiovasc Pharmacol 1993;22 Suppl 8:S181-4.
11. Yoshida K, Yasujima M, Kohzuki M, Kanazawa M, Yoshinaga K, Abe K. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 1992;20:292-7.
12. Yang ZH, Richard V, von Segesser L, Bauer E, Stulz P, Turina M, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation 1990;82:188-95.
13. Rakugi H, Tabuchi Y, Nakamaru M, Nagano M, Higashimori K, Mikami H, et al. Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries. Biochem Int 1990;21: 867-72.
14. Cozza EN, Gomez-Sanchez CE. Mechanisms of ET-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol 1993;265:E179-83.
15. Hinson JP, Vinson GP, Kapas S, Teja R. The role of endothelin in the control of adrenocortical function: stimulation of endothelin release by ACTH and the effects of endothelin-1 and endothelin-3 on steroidogenesis in rat and human adrenocortical cells. J Endocrinol 1991;128:275-80.
16. Sütsch G, Bertel O, Rickenbacher P, Clozel M, Yandle TG, Nicholls MG, et al. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol 2000;85:973-6.
17. Thiemermann C, Lidbury PS, Thomas GR, Vane JR. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized rabbit. J Cardiovasc Pharmacol 1989;13 Suppl 5:S138-41.
18. Miura K, Yukimura T, Yamashita Y, Shimmen T, Okumura M, Yamanaka S, et al. Renal and femoral vascular responses to endothelin-1 in dogs: role of prostaglandins. J Pharmacol Exp Ther 1991;256:11-7.
19. Schumacher WA, Steinbacher TE, Allen GT, Ogletree ML. Role of thromboxane receptor activation in the bronchospastic response to endothelin. Prostaglandins 1990;40:71-9.
20. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998;31 Suppl 1:S360-3.
21. B receptors. Br J Pharmacol 1995;115:227-36.
22. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998;31 Suppl 1:S545-7.
23. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14: 385-99.
24. Douglas SA, Ohlstein EH. Signal transduction mechanisms mediating the vascular actions of endothelin. J Vasc Res 1997;34: 152-64.
25. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
26. Marini M, Carpi S, Bellini A, Patalano F, Mattoli S. Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem Biophys Res Commun 1996;220:896-9.
27. Shi-wen X, Denton CP, Dashwood MR, Holmes AM, BouGharios G, Pearson JD, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-25.
28. Hafstrom I, Ringertz B, Lundeberg T, Palmblad J. The effect of endothelin, neuropeptide Y, calcitonin gene-related peptide and substance P on neutrophil functions. Acta Physiol Scand 1993; 148:341-6.
29. Halim A, Kanayama N, el Maradny E, Maehara K, Terao T. Activated neutrophil by endothelin-1 caused tissue damage in human umbilical cord. Thromb Res 1995;77:321-7.
30. Uchida Y, Ninomiya H, Sakamoto T, Lee JY, Endo T, Nomura A, et al. ET-1 released histamine from guinea pig pulmonary but not peritoneal mast cells. Biochem Biophys Res Commun 1992; 189:1196-201.
31. McMillen MA, Sumpio BE. Endothelins: polyfunctional cytokines. J Am Coll Surg 1995;180:621-37.
32. Hosoda K, Nakao K, Arai H, Suga S, Ogawa Y, Mukoyama M, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991;287:23-6.
33. Simonson MS, Osanai T, Dunn MJ. Endothelin isopeptides evoke Ca2+ signaling and oscillations of cytosolic free [Ca2+] in human mesangial cells. Biochim Biophys Acta 1990;1055:63-8.
34. Neylon CB, Avdonin PV, Dilley RJ, Larsen MA, Tkachuk VA, Bobik A. Different electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell types. Circ Res 1994;75:733-41.
35. B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996;119:1125-30.
36. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91: 1367-73.
37. Filep JG, Hermán F, Battistini B, Chabrier PE, Braquet P, Sirois P. Antiaggregatory and hypotensive effects of endothelin-1 in beagle dogs: role for prostacyclin. J Cardiovasc Pharmacol 1991;17 Suppl 7:S216-8.
38. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996;94:2131-7.
39. Kakoki M, Hirata Y, Hayakawa H, Tojo A, Nagata D, Suzuki E, et al. Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 1999;99:1242-8.
40. B receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol 1999;276:H1197-206.
41. Yokoyama Y, Baveja R, Sonin N, Nakanishi K, Zhang JX, Clemens MG. Altered endothelin receptor subtype expression in hepatic injury after ischemia/reperfusion. Shock 2000;13:72-8.
42. Lauth M, Berger MM, Cattaruza M, Hecker M. Elevated perfusion pressure upregulates endothelin-1 and endothelin B receptor expression in the rabbit carotid artery. Hypertension 2000;35: 648-54.
43. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO III, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999;33:753-8.
44. Abraham DJ, Vancheeswaran R. Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997; 151:831-41.
45. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 1993;27: 2125-9.
46. B receptors. Am J Physiol 1997;272:L1021-4.
47. Rebuffat P, Aragona F, Tortorella C, Malendowicz LK, Nussdorfer GG. Signaling pathways involved in the A and B receptormediated cortisol secretagogue effect of endothelins in the human adrenal cortex. Int J Mol Med 2001;7:301-5.
48. B receptor subtypes. J Clin Endocrinol Metab 1997;82:3445-9.
49. Rossi GP, Andreis PG, Neri G, Tortorella C, Pelizo MR, Sacchetto A, et al. Endothelin-1 stimulates aldosterone synthesis in Conn's adenomas via both A and B receptors coupled with the protein kinase C- and cyclooxygenase-dependent signaling pathways. J Investig Med 2000;48:343-50.
50. Belloni AS, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC, et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension 1996;27:1153-9.
51. B receptor antagonist in heart failure. Cardiovasc Res 1998;39:617-24.
52. B receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997;30:1385-92.
53. Chen SJ, Chen YF, Meng QC, Durand J, DiCarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79: 2122-31.
54. Holm P, Liska J, Clozel M, Franco-Cereceda A. The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg 1996;112:890-7.
55. A receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997;282:1312-8.
56. Tilton RG, Munsch CL, Sherwood SJ, Chen SJ, Chen YF, Wu C, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther 2000;13:87-97.
57. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8.
58. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
59. Rubin LJ, Badesch DB, Barst RJ, Galié N, Black CM, Deogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
60. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999;61:391-415.
61. Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995;287:439-42.
62. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V, et.al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995;99:255-60.
63. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R. et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
64. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566-71.
65. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990;336:1144-7.
66. Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus [letter]. Ann Rheum Dis 1991;50: 526-7.
67. Kanno K, Hirata Y, Numano F, Emori T, Ohta K, Shichiri M, et al. Endothelin-1 and vasculitis [letter]. JAMA 1990;264:2868.
68. Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, et al. Elevated expression of endothelin-I and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-93.
69. Peacock AJ. Primary pulmonary hypertension. Thorax 1999;54: 1107-18.
70. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
71. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001;40:453-9.
72. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29: 515-24.
73. Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
74. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990;21:467-74.
75. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). QJM 1992; 82:139-48.
76. Marié I, Levesque H, Hatron PY, Dominique S, Courtois H. Pulmonary involvement in systemic scleroderma. Part II. Isolated pulmonary arterial hypertension, bronchopulmonary cancer, alveolar hemorrhage. Rev Med Interne 1999;20:1017-27.
77. Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-9.
78. Gaine S. Pulmonary hypertension. JAMA 2000;284:3160-8.
79. Ishikawa S, Miyauchi T, Ueno H, Ushinohama H, Sagawa K, Fusazaki N, et al. Influence of pulmonary blood pressure and flow on endothelin-1 production in humans. J Cardiovasc Pharmacol 1995;26 Suppl 3:S429-33.
80. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991;88:1054-7.
81. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328: 1732-9.
82. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.
83. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation 1991;84:2280-5.
84. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995;268: H828-35.
85. Clozel M, Breu V, Gray GA, Kalina B, Loffler B-M, Burri K, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
86. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53: 506-10.
87. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-76.
88. Cambrey AD, Harrison NK, Dawes KE, Southcott AM, Black CM, du Bois RM, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Bio 1994;11:439-45.
89. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980;59:393-408.
90. Gahhos F, Ariyan S, Frazier WH, Cuono CB. Management of sclerodermal finger ulcers. J Hand Surg (Am) 1984;9:320-7.
91. Della Rossa A, Valentini G, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis: I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001;60:585-91.
92. Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670-7.
93. Black C, Korn J, Mayes M, Rainisio M, Gaitonde M, Nguyen N, the RAPIDS-1 Study Group. Prevention of ischemic digital ulcers in systemic sclerosis by endothelin receptor antagonism [abstract]. Arthritis Rheum 2002;46:3414-5.
94. Belch JJ. Raynaud's phenomenon. Curr Opin Rheumatol 1989; 1:490-8.
95. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991;283: 366-71.
96. Biondi ML, Marasini B, Bassani C, Agastoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 1991;324:1139-40.
97. Cimminiello C, Milani M, Uberti T, Arpaia G, Perolini S, Bonfardeci G. Endothelin, vasoconstriction, and endothelial damage in Raynaud's phenomenon. Lancet 1991;337:114-5.
98. Ferri C, Latorraca A, Catapano G, Greco F, Mazzoni A, Clerico A, et al. Increased plasma endothelin-1 immunoreactive levels in vasculitis: a clue to the use of endothelin-1 as a marker of vascular damage? J Hypertens 1993;11 Suppl 5:S142-3.
99. Leppert J, Ringqvist A, Karlberg BE, Ringqvist I. Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud's phenomenon. Clin Physiol 1998;18:420-5.
100. Sakamoto K, Houya I, Inoue K, Tanaka M, Suzuki T, Sakamoto Y, et al. An imbalance in plasma prostanoids in patients with Raynaud's phenomenon and pulmonary vasospasm. Eur Respir J 1999;13:137-44.
101. Smyth AE, Bell AL, Bruce IN, McGrann S, Allen JA. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 2000;59:870-4.
102. Silveri F, De Angelis R, Poggi A, Muti S, Bonapace G, Argentati F, et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001;30: 290-6.
103. Biondi ML, Marasini B. Abnormal platelet aggregation in patients with Raynaud's phenomenon. J Clin Pathol 1989;42:716-8.
104. Coffman JD, Cohen RA. Serotonergic vasoconstriction in human fingers during reflex sympathetic response to cooling. Am J Physiol 1988;254:H889-93.
105. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 1995;54:361-5.
106. Matsuda J, Tsukamoto M, Gohchi K, Saitoh N, Miyajima Y, Kazama M. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. Acta Haematol 1992;88:189-93.
107. Akazawa H, Ikeda U, Kuroda T, Shimada K. Plasma endothelin-1 levels in Takayasu's arteritis. Cardiology 1996;87:303-5.
108. Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipo I, Szegedi G. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation 1995; 92:2969-74.